Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | ACACA | Q13085 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946009 | 0.87 | MAOB (0.50) | MAOBSMN1; SMN2TDP1PTGER1 | |
| SCHEMBL14339676 | 0.86 | ABCB1 (0.47) | MAOBNPC1RAB9AABCB1 | |
| SCHEMBL29788601 | 0.86 | MAOB (0.57) | MAOBNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL1971024 | 0.86 | MAOB (0.57) | MAOBNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL24978176 | 0.84 | MAOB (0.48) | MAOBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7405753 | 0.84 | PDE4B (0.47) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL4946263 | 0.83 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DACACA | |
| SCHEMBL24978450 | 0.81 | MAOB (0.73) | MAOBNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL4941339 | 0.80 | NPC1 (0.53) | MAOBNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL30800458 | 0.80 | MAOB (0.53) | MAOBNPC1RAB9APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | MURATA TOSHIKI | 2009-02-26 | — | — | US | disclosed |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | MURATA TOSHIKI | 2009-02-26 | — | — | US | disclosed |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | MURATA TOSHIKI | 2009-02-26 | — | — | US | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| EP-1487842-B1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | BAYER HEALTHCARE AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060100246-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| US-20050215547-A1 | Optically active pyridine derivative and a medicament containing the same | BAYER HEALTHCARE AG (DE) | 2005-09-29 | — | — | US | disclosed |
| EP-1487842-A1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | Bayer HealthCare AG (DE) | 2004-12-22 | — | — | EP | disclosed |
| US-20040097563-A1 | 4-6-Diphenyl pyridine derivatives as antiinflammatory agents | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| WO-2003076447-A1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | BAYER HEALTHCARE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097563-A1 | 4-6-Diphenyl pyridine derivatives as antiinflammatory agents | IL6, HRH4, CXCR6 | MAOB 2657/4885PDE4A 1265/4885PDE4B 1439/4885 |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MAOB 4683/4885PDE4A 2621/4885PDE4B 2848/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | MAOB 4683/4885PDE4A 2621/4885PDE4B 2848/4885 |
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | MAOB 3448/4885PDE4A 2379/4885PDE4B 1754/4885 |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | IL1B, NFKBIA, IL17A | MAOB 2162/4885PDE4A 150/4885PDE4B 252/4885 |
| US-20060100246-A1 | Pyridine derivatives | NAPRT, NNT, NANS | MAOB 340/4885PDE4A 228/4885PDE4B 276/4885 |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MAOB 4683/4885PDE4A 2621/4885PDE4B 2848/4885 |
| US-20050215547-A1 | Optically active pyridine derivative and a medicament containing the same | IL1B, NFKBIA, IL1A | MAOB 2281/4885PDE4A 131/4885PDE4B 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.